Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. - Desai AV; Applebaum MA; Karrison TG; Oppong A; Yuan C; Berg KR; MacQuarrie K; Sokol E; Hall AG; Pinto N; Wolfe I; Mody R; et al. (Cancer, 2022)